Although the company spun off its diagnostics and biosciences arm in February 2026, buying Becton Dickinson stock still works the ordinary way: open a brokerage account that reaches the New York Stock Exchange and order the common shares under the ticker BDX. The share now stands for a narrower BD, built on catheters, syringes, infusion pumps and prefillable syringes for drugmakers; its filings put hernia-device lawsuits and an FDA consent decree over Alaris pumps near the top of the risk list.
What Does Becton Dickinson Do?
Becton, Dickinson and Company, known as BD, describes itself as "a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies and devices." Its New Jersey incorporation dates to November 1906, succeeding a New York business started in 1897.
Acquisitions built much of it: CareFusion, maker of the Alaris infusion pumps, in 2015; C.R. Bard in December 2017; and Edwards Lifesciences' Critical Care product group, agreed in June 2024 and completed on 3 September 2024 as BD Advanced Patient Monitoring. Other parts left: diabetes care became the separately listed Embecta on 1 April 2022, and on 9 February 2026 BD completed the spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters Corporation in a Reverse Morris Trust. BD shareholders received Waters stock representing 39.2% of the combined company on a fully diluted basis.
Four segments remain:
Medical Essentials: IV catheters, syringes and needles, flush syringes and BD Vacutainer blood collection.
Connected Care: infusion pumps and their disposables, automated dispensing and the hemodynamic monitors bought from Edwards.
BioPharma Systems: prefillable syringes and self-injection systems that drugmakers fill and sell as drug-device combinations.
Interventional: angioplasty balloons, stents, atherectomy systems and ports; urology products such as PureWick; and surgery products including hernia repair and ChloraPrep.
How Becton Dickinson Makes Money
BD's fiscal year ends on 30 September. Fiscal 2025 revenue grew 8.2%: the Advanced Patient Monitoring acquisition added 4.8%, volume and other items 3.2%, and pricing subtracted 0.3%.
The fiscal 2025 10-K used three older segments; regrouped into today's structure, its unit revenue splits like this:
| Segment | Share of fiscal 2025 revenue |
|---|---|
| Medical Essentials | 29.5% |
| Connected Care | 20.9% |
| BioPharma Systems | 10.6% |
| Interventional | 23.9% |
| Life Sciences, now part of Waters | 15.1% |
Percentages divide unit revenue in the 10-K by the year's total; BD's February 2026 recast gives the same totals.
So the four segments BD kept produced about 85% of that year's revenue, much of it from disposables sold through distributors under what BD calls a "highly recurring consumables model"; "our capital equipment is mostly sold direct to our end user customers."
About 59% of fiscal 2025 revenue came from the United States and 41% from elsewhere, and BD manufactures in 18 other countries, from Brazil and Mexico to China and India.
BDX Stock at a Glance
| Item | Detail |
|---|---|
| Exchange | New York Stock Exchange (NYSE) |
| Ticker | BDX |
| Security | Common stock; no other equity class on the 10-K cover |
| Other listed securities | Five note series, for example BDX31 |
| Sector | Healthcare: medical technology |
| Index membership | S&P 500 |
| Headquarters | Franklin Lakes, New Jersey |
| Fiscal year | Ends on 30 September |
| Dividend policy | Quarterly; raised in November 2025 for a 54th consecutive fiscal year |
| SEC identifier | CIK 10795 |
None of this moves with the market; for price, market value and yield, open the Becton Dickinson stock page on Bitbase.
How to Buy Becton Dickinson Stock
BD is American and listed at home, so no depositary receipt sits in between. The order takes six steps:
1. Choose a broker with NYSE access. Confirm the legal entity behind the account and its regulator.
2. Pass verification. Non-US individuals usually file IRS Form W-8BEN, which is how a broker applies a reduced treaty rate, if one exists, to US dividends.
3. Fund it. Currency conversion costs count alongside commission.
4. Find the right line. Search BDX and confirm the listing is Becton, Dickinson and Company common stock; BDX31 and similar symbols are BD's bonds.
5. Pick an order type. In FINRA's words, a market order "provides the most certainty that your order will be executed," while a limit order fills only "at or better than a specified price," with "a chance your order doesn't get executed at all."
6. Set the size. Some brokers "don't offer fractional share trading at all," and fractions may come without voting rights.
Where pre-market or after-hours orders are allowed, remember that thin after-hours trading can print prices away from the regular session.
Dividend tax for non-US holders. According to the IRS, "most types of U.S. source income received by a foreign person are subject to U.S. tax of 30%," and a treaty may lower that. Your home country may tax the payment again.
Through a fund. BD also sits inside State Street's S&P 500 fund, SPY, and its Health Care Select Sector SPDR ETF (XLV).
What Moves BDX Stock
A reshaped company. Results after February 2026 exclude the diagnostics and biosciences business, and BD used the cash it received from the spin-off company for an accelerated share repurchase and debt repayment, so per-share figures shift too.
Infusion pumps under a consent decree. BD's US infusion pumps fall under a decree first entered in 2007 and amended in 2009 to cover all CareFusion 303 pumps. The FDA cleared an updated BD Alaris Infusion System on 21 July 2023, allowing a return to market. That return lifted Alaris sales a year earlier, and in the June 2026 quarter BD cited "an unfavorable comparison" with them.
China's purchasing programmes. The 10-K cites "market dynamics in China, such as volume-based procurement programs," which in fiscal 2025 offset part of the growth in vascular access and peripheral intervention.
Drug-delivery demand. BioPharma Systems depends on pharmaceutical customers' orders. In the June 2026 quarter its growth came from prefillable solutions for biologic drugs, "led by sales of GLP-1 delivery products," while weaker vaccine demand held it back.
Tariffs and restructuring. BD expects tariffs to weigh on operating expense "for fiscal year 2026 and potentially beyond," and in the June 2026 quarter tariffs, labour and currency lowered the Medical Essentials gross margin. Its Excellence Unleashed strategy also brought non-cash impairment charges in the March 2026 quarter.
Litigation, FDA Oversight and Debt at Becton Dickinson
Of the risk factors in the fiscal 2025 10-K, these bear most directly on a BDX share:
Lawsuits. "We are subject to lawsuits." As of 30 June 2026 BD was defending about 7,090 product liability claims over hernia repair devices, although a fiscal 2024 settlement is meant to resolve "the vast majority of its existing hernia litigation." Other suits concern pelvic mesh, vena cava filters, implantable ports and ethylene oxide exposure near its sterilization facilities in Covington, Georgia.
Quality and regulators. "Defects or quality issues associated with our products and related regulatory actions could adversely affect our results of operations and financial statements." After any future violation, the Alaris decree lets the FDA order BD to stop making and distributing infusion pumps. In December 2024 BD also settled an SEC matter over Alaris-related reporting in disclosures made before 2021.
Sterilization. "Interruption of our manufacturing or sterilization operations could adversely affect our business." Ethylene oxide is "the most frequently used sterilant for medical devices and healthcare products in the United States," and regulators are watching its emissions.
Competition and pricing. "The medical technology industry is very competitive," and tenders, volume-based procurement and government payback rules have cut selling prices in some countries.
Debt. "We may not be able to service all of our indebtedness." The 10-K adds that refinancing could be harder after BD lost its "well-known seasoned issuer" status, a result of the December 2024 SEC order.
The stock adds its own risks: one company concentrates the outcome, each dividend is declared separately, and outside the dollar both price and dividend pass through an exchange rate.
A Reading Guide to BD's SEC Filings
BD files under CIK 10795: the 10-K after each fiscal year, 10-Qs for the December, March and June quarters, and 8-Ks in between, such as the Waters closing on 9 February 2026.
Three checks help. Fiscal 2026 filings exclude the former Biosciences and Diagnostic Solutions business, which the fiscal 2025 10-K still includes; the 8-K of 5 February 2026 restates fiscal 2025 revenue by new segment. Specimen Management moved from the old Life Sciences segment into Medical Essentials and stayed with BD. And of the six securities on the June 2026 10-Q cover, only the common stock uses the bare BDX symbol.
Other companies are in the full list of Bitbase stock pages; for another healthcare group reshaped by separation, see Johnson & Johnson's exit from Kenvue.
Becton Dickinson Stock FAQ
Does Becton Dickinson pay a dividend?
Yes, every quarter. In November 2025 the board raised it by 1.0%, which BD called "the 54th consecutive fiscal year in which we have raised our dividend," keeping it in the S&P 500 Dividend Aristocrats Index.
Can I buy Becton Dickinson stock with crypto?
Not directly. BDX is bought through a broker and trades on the NYSE settle in dollars, so you would sell the crypto first and transfer the cash; depending on your country, that sale can be taxable. Keep the decisions separate, because a share and a crypto token carry different rights.
What did BDX shareholders receive in the Waters deal?
Holders of record at the close of business on 5 February 2026 received one spin-off share per BD share, each converted into about 0.135 Waters shares, with cash instead of fractions. They kept their BDX shares.
Is BDX in the S&P 500?
Yes. State Street's holdings files for SPY and XLV, dated 29 October 2026, both list Becton Dickinson. Weights change daily.
Has Becton Dickinson stock ever split?
Yes. Its 1990s annual reports record two-for-one splits in 1993 and August 1996 and another distributed in August 1998 to holders of record on 10 August 1998, so older per-share figures need adjusting.
Conclusion
Buying BDX takes an NYSE-enabled broker, the correct ticker line and a market or limit order. Knowing what the share holds takes longer: since February 2026 it is catheters, syringes, pumps, drug-delivery systems and interventional devices, without the diagnostics unit now at Waters. Read the newest 10-K and 10-Q, litigation note included, before sizing a position.
Related reading
Other Bitbase articles on this topic:
- How to Buy Boston Scientific Stock (BSX): Farapulse and Watchman
- How to Buy Cardinal Health Stock (CAH): CVS, Generics, Opioids
- How to Buy Cencora Stock (COR): Ex-AmerisourceBergen, Walgreens
- How to Buy Elevance Health Stock (ELV): Anthem, BCBS, Carelon
Disclaimer: This article is educational content from Bitbase Academy, provided for information only. It explains what a company or fund does and how the instruments referenced here differ from one another; it does not constitute investment, trading, tax, or financial advice, and it is neither a recommendation nor an endorsement of any security, token, or trading strategy. A tokenized stock is issued by a third party and is designed to give economic exposure to an underlying asset: it is not a share, it carries no shareholder rights, and it depends on the issuer's structure, eligibility rules, and redemption terms, which the issuer can change. Perpetual futures are leveraged derivatives that hold no underlying asset and can be liquidated, and trading hours, product availability, and eligibility differ by instrument and by jurisdiction and can change at any time. Written as of October 2026; verify everything yourself through company filings, the issuer's own documentation, and the product pages of the venue you trade on.
References
[1] Becton, Dickinson and Company Form 10-K, fiscal 2025 (SEC EDGAR) www.sec.gov
[2] Becton, Dickinson and Company Form 10-Q, quarter ended 30 June 2026 (SEC EDGAR) www.sec.gov
[3] BD 8-K on completing the Waters transaction, 9 February 2026 (SEC EDGAR) www.sec.gov
[4] BD 8-K with fiscal 2025 revenue recast into the new segments, 5 February 2026 (SEC EDGAR) www.sec.gov
[5] BD 8-K on the agreement to acquire Edwards Lifesciences' Critical Care group, 3 June 2024 (SEC EDGAR) www.sec.gov
[6] BD, BD Board Increases Dividend for 54th Consecutive Year, 6 November 2025 news.bd.com
[7] Becton, Dickinson and Company Form 10-K, fiscal 1998: stock splits (SEC EDGAR) www.sec.gov
[8] State Street, SPY daily holdings, 29 October 2026 www.ssga.com
[9] State Street, XLV daily holdings, 29 October 2026 www.ssga.com
[10] FINRA, Order Types www.finra.org
[11] FINRA, Investing in Fractional Shares www.finra.org
[12] IRS, NRA Withholding www.irs.gov






